MARKET IS CLOSED
Loading latest tickers...
Market Indices
S&P 500
$7,666.45
+0.19%
NASDAQ 100
$30,501.56
+0.31%
DOW JONES
$50,927.00
+0.04%
NASDAQ Composite
$26,871.60
+0.04%
RUSSELL 2000
$2,790.20
+0.41%
CBOE VIX
$16.39
+0.31%
Sector Heatmap
Technology+1.05%
Financials+0.11%
Healthcare-1.32%
Consumer Cycl-0.03%
Consumer Staples-0.33%
Energy+1.95%
Industrials+0.99%
Materials-0.33%
Real Estate-0.56%
Utilities+0.61%
Comm Services-0.93%
ABEO — Abeona Therapeutics Inc. Common Stock
NasdaqAbeona Therapeutics Inc. Common Stock
$5.00
-0.25(-4.76%)
- O
- 5.22
- H
- 5.25
- L
- 4.99
- V
- 1.44M
⏱️ End-of-day dataAs of Oct 1, 2026
Chart
About ABEO
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
IndustryPHARMACEUTICAL PREPARATIONS
SectorNot available
IPO DateSep 19, 1980
Employees226
Stock ExchangeNasdaq
Ticker SymbolABEO
Key Financial Statistics
| Market Cap | $308.79M |
| P/E Ratio | N/A |
| Dividend Yield | N/A |
| EPS | N/A |
| Beta | N/A |
| 52-Week Range | $2.19 - $5,437,500.00 |
| 52-Week Avg Volume | 70.1K |
| VWAP | $5.12 |
| Transactions | 9,130 |
| Total Recorded Bars | 11,600 days |